全文获取类型
收费全文 | 6229篇 |
免费 | 294篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 133篇 |
妇产科学 | 126篇 |
基础医学 | 649篇 |
口腔科学 | 253篇 |
临床医学 | 430篇 |
内科学 | 1737篇 |
皮肤病学 | 185篇 |
神经病学 | 383篇 |
特种医学 | 151篇 |
外科学 | 1025篇 |
综合类 | 25篇 |
预防医学 | 478篇 |
眼科学 | 135篇 |
药学 | 276篇 |
中国医学 | 17篇 |
肿瘤学 | 450篇 |
出版年
2024年 | 4篇 |
2023年 | 30篇 |
2022年 | 71篇 |
2021年 | 185篇 |
2020年 | 83篇 |
2019年 | 145篇 |
2018年 | 238篇 |
2017年 | 120篇 |
2016年 | 148篇 |
2015年 | 146篇 |
2014年 | 241篇 |
2013年 | 262篇 |
2012年 | 472篇 |
2011年 | 439篇 |
2010年 | 268篇 |
2009年 | 275篇 |
2008年 | 407篇 |
2007年 | 445篇 |
2006年 | 399篇 |
2005年 | 413篇 |
2004年 | 348篇 |
2003年 | 316篇 |
2002年 | 300篇 |
2001年 | 72篇 |
2000年 | 98篇 |
1999年 | 105篇 |
1998年 | 46篇 |
1997年 | 39篇 |
1996年 | 40篇 |
1995年 | 29篇 |
1994年 | 25篇 |
1993年 | 18篇 |
1992年 | 39篇 |
1991年 | 45篇 |
1990年 | 26篇 |
1989年 | 29篇 |
1988年 | 19篇 |
1987年 | 23篇 |
1986年 | 17篇 |
1985年 | 13篇 |
1984年 | 11篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 20篇 |
1980年 | 9篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 9篇 |
1944年 | 4篇 |
排序方式: 共有6549条查询结果,搜索用时 15 毫秒
111.
Guevara M Fernández-Esparrach G Alessandria C Torre A Terra C Montañà X Piera C Alvarez ML Jiménez W Ginès P Arroyo V 《Hepatology (Baltimore, Md.)》2004,40(3):646-651
Patients with cirrhosis are frequently submitted to radiological procedures that require the administration of contrast media. Contrast media is a well-known cause of renal failure, particularly in the presence of some predisposing conditions. However, it is not known whether cirrhosis constitutes a risk factor for contrast media-induced renal failure. The aim of this study was to assess the possible nephrotoxicity of contrast media in patients with cirrhosis. In a first protocol, renal function was evaluated with sensitive methods (glomerular filtration rate using iothalamate I 125 clearance and renal plasma flow using iodohippurate I 131 clearance) before and 48 hours after the administration of contrast media in 31 patients with cirrhosis (20 with ascites, 5 with renal failure). Solute-free water clearance, urine sodium, prostaglandins, and markers of tubular damage were also measured. The administration of contrast media was not associated with significant changes in renal function tests, neither in the whole group of patients nor in patients with ascites or renal failure. Urinary prostaglandin E2 and N-acetyl-beta-D-glucosaminidase increased significantly, but sodium and solute-free water excretion remained unchanged. In a second protocol, a different series of 60 patients with cirrhosis and renal failure were examined prospectively. No patient had renal failure due to contrast media. Only in 1 patient with septic shock was contrast media a possible contributing factor. In conclusion, the administration of contrast media is not associated with adverse effects on renal function in patients with cirrhosis. Cirrhosis does not appear to be a risk factor for the development of contrast media-induced nephrotoxicity. 相似文献
112.
113.
Alicia Calvo-Fernández Andrea Izquierdo Isaac Subirana Nuria Farré Joan Vila Xavier Durán Marcos García-Guimaraes Sandra Valdivielso Paula Cabero Cristina Soler Cora García-Ribas Clara Rodríguez Marc Llagostera Diana Mojón Miren Vicente Eduard Solé-González Andrea Sánchez-Carpintero Cristina Tevar Beatriz Vaquerizo 《Revista espa?ola de cardiología》2021,74(7):576-583
Introduction and objectivesCOVID-19 is currently causing high mortality and morbidity worldwide. Information on cardiac injury is scarce. We aimed to evaluate cardiovascular damage in patients with COVID-19 and determine the correlation of high-sensitivity cardiac-specific troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) with the severity of COVID-19.MethodsWe included 872 consecutive patients with confirmed COVID-19 from February to April 2020. We tested 651 patients for high-sensitivity troponin T (hs-TnT) and 506 for NT-proBNP on admission. Cardiac injury was defined as hs-TnT > 14 ng/L, the upper 99th percentile. Levels of NT-proBNP > 300 pg/mL were considered related to some extent of cardiac injury. The primary composite endpoint was 30-day mortality or mechanical ventilation (MV).ResultsCardiac injury by hs-TnT was observed in 34.6% of our COVID-19 patients. Mortality or MV were higher in cardiac injury than noncardiac injury patients (39.1% vs 9.1%). Hs-TnT and NT-proBNP levels were independent predictors of death or MV (HR, 2.18; 95%CI, 1.23-3.83 and 1.87 (95%CI, 1.05-3.36), respectively) and of mortality alone (HR, 2.91; 95%CI, 1.211-7.04 and 5.47; 95%CI, 2.10-14.26, respectively). NT-ProBNP significantly improved the troponin model discrimination of mortality or MV (C-index 0.83 to 0.84), and of mortality alone (C-index 0.85 to 0.87).ConclusionsMyocardial injury measured at admission was a common finding in patients with COVID-19. It reliably predicted the occurrence of mortality and need of MV, the most severe complications of the disease. NT-proBNP improved the prognostic accuracy of hs-TnT. 相似文献
114.
David Vivas Inmaculada Roldán Raquel Ferrandis Francisco Marín Vanessa Roldán Antonio Tello-Montoliu Juan Miguel Ruiz-Nodar Juan José Gómez-Doblas Alfonso Martín Juan Vicente Llau María José Ramos-Gallo Rafael Muñoz Juan Ignacio Arcelus Francisco Leyva Fernando Alberca Raquel Oliva Ana María Gómez Carmen Montero Andrés Íñiguez 《Revista espa?ola de cardiología》2018,71(7):553-564
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice.Full English text available from: www.revespcardiol.org/en 相似文献
115.
116.
Corinne Antignac James P. Calvet Gregory G. Germino Jared J. Grantham Lisa M. Guay-Woodford Peter C. Harris Friedhelm Hildebrandt Dorien J.M. Peters Stefan Somlo Vicente E. Torres Gerd Walz Jing Zhou Alan S.L. Yu 《Journal of the American Society of Nephrology : JASN》2015,26(9):2081-2095
Polycystic kidney disease (PKD) is one of the most common life-threatening genetic diseases. Jared J. Grantham, M.D., has done more than any other individual to promote PKD research around the world. However, despite decades of investigation there is still no approved therapy for PKD in the United States. In May 2014, the University of Kansas Medical Center hosted a symposium in Kansas City honoring the occasion of Dr. Grantham''s retirement and invited all the awardees of the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease to participate in a forward-thinking and interactive forum focused on future directions and innovations in PKD research. This article summarizes the contributions of the 12 Kaplan awardees and their vision for the future of PKD research. 相似文献
117.
Genotype–Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers 下载免费PDF全文
Soley Bayraktar MD MBA Michelle Jackson MS Angelica M. Gutierrez‐Barrera MS Diane Liu MS Funda Meric‐Bernstam MD Amanda Brandt MS Ashley Woodson MS Jennifer Litton MD Karen H. Lu MD Vicente Valero MD Banu K. Arun MD 《The breast journal》2015,21(3):260-267
The genotype–phenotype correlations of the specific BRCA1 and BRCA2 mutations in multi‐ethnic populations in USA have not yet been fully investigated. This study was designed to evaluate the effects of ethnicity at specific mutation locations and breast/ovarian cancer phenotypes. Our cohort included 445 women with different ethnic backgrounds who underwent BRCA genetic testing between 1997 and 2010. Known clinical and pathologic characteristics were compared with Chi‐Square Analysis or Fisher's Exact test as appropriate. The three most common mutation locations in BRCA1 (exons 2, 11, and 20) and BRCA2 (exons 10, 11, and 25) genes were chosen. Prevalence of BRCA1 exon 2 mutations were significantly higher in Ashkenazi Jewish (AJ) women compared to Caucasians (41% versus 15%; p = 0.001). Similarly, AJ women with breast cancer were more likely to have BRCA1 exon 2 mutation (47% positivity in AJ women versus 0–12.5% positivity in other ethnicities; p = 0.004). Women carrying the exon 20 BRCA1 mutation had the highest probability of having combined breast and ovarian cancers compared to women carrying other exon mutations (p = 0.05). The median age at initial cancer diagnosis, phenotypic features of breast cancer tumors, and overall survival did not vary significantly by ethnicity or mutation location. Our data suggest that ethnicity does not affect age of onset, overall survival or confer different risks of breast and ovarian cancer development in BRCA carriers. These results also suggest that women carrying the exon 20 BRCA1 mutation may warrant mutation‐specific counseling and be more aggressively managed for risk reduction. 相似文献
118.
Paulo Roberto Santos Diego Levi Silveira Monteiro Paulo Henrique Alexandre de Paula Vicente Lopes Monte Neto Maria Leilah Ponte Monte Coelho Cecília Costa Arcanjo Sânkia Maria Lopes Aragão Camila Barbosa Gondim Janaína Teixeira Pereira Carneiro Tapeti Hyngridd Soares Mendes Luise Vasconcelos Vieira Rita de Cássia Parente Prado 《Nephrology (Carlton, Vic.)》2015,20(8):519-522
119.
120.
Hypertrophic cardiomyopathy linked to homozygosity for a new mutation in the myosin-binding protein C gene (A627V) suggests a dosage effect 总被引:3,自引:0,他引:3
García-Castro M Reguero JR Alvarez V Batalla A Soto MI Albaladejo V Coto E 《International journal of cardiology》2005,102(3):501-507
Mutations in the cardiac myosin-binding protein C gene (MYBPC3) are responsible for up to 50% of familial cases with hypertrophic cardiomyopathy (HC). Compared to patients with mutations in other sarcomeric genes, patients with MYBPC3 mutations would have a milder form of the disease, with a lower incidence of sudden cardiac death. Because most of the mutations have been found in only one family, it is currently difficult to establish a correlation between a particular mutation and the HC phenotype. The aim of our study was to contribute to understanding of the role of MYBPC3 mutations in HC. We analysed the MYBPC3 exons and intron flanking regions in 10 patients from 10 families with at least two HC cases. After direct sequencing of polymerase chain reaction (PCR) fragments, we found three new mutations in three families (V771M, V342D, and A627V). These changes affected evolutionary conserved amino acids and were not found in 100 healthy controls. The Ala 627>Val was found homozygous in a 47-year-old patient with a severe form of HC, while his mother and a nephew were heterozygous carriers and asymptomatic. This fact suggests a dosage effect for mutations at the MYPBC3 gene. 相似文献